Company intelligence / Profile preview
Dispatch Bio
Philadelphia, Pennsylvania, United Statesdispatchbio.com ↗
- Ownership
- Private
- Employees
- ~60
- Development stage
- Other
01
Overview
Dispatch Bio has raised $216 million to advance a universal immunotherapy platform targeting solid tumors using the engineered 'flare' antigen installed on tumor cells, with backing from ARCH Venture Partners and Parker Institute for Cancer Immunotherapy. The approach remains pre-clinical, with no published human efficacy data yet.[1][4][5][7]
- Therapeutic areas
- Oncology
- Modalities
- Gene therapyViral vectorImmunotherapyProteinCell therapy
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
ARCH Venture PartnersParker Institute for Cancer ImmunotherapyUniversity of Pennsylvania
Beyond the preview
Go deeper on Dispatch Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dispatch Bio.